Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Directly Reprogramming Nerve Cells in the Brain

By BiotechDaily International staff writers
Posted on 04 Apr 2013
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Generating new cells in the body to cure disease, the purview of cell therapy, has taken another significant step in the development toward new treatments. New Swedish research demonstrated that it is possible to reprogram other cells to become nerve cells, directly in the brain.

Two years ago, researchers in Lund University (Sweden) were the first in the world to reprogram fibroblasts to dopamine-producing nerve cells, without going through the stem cell stage. The scientists are now going further and shown that it is possible to reprogram both skin cells and support cells directly to nerve cells, in place in the brain.

“The findings are the first important evidence that it is possible to reprogram other cells to become nerve cells inside the brain,” said Dr. Malin Parmar, research group leader and reader in neurobiology at Lund.

The researchers employed genes designed to be switched on or off using a drug. The genes were inserted into two types of human cells, glia cells and fibroblasts, support cells that are naturally present in the brain. Once the researchers had transplanted the cells into the brains of rats, the genes were triggered using a drug in the animals’ drinking water. The cells then began their conversion into nerve cells.

In other research with lab mice, where similar genes were injected into the mice’s brains, the investigators also were able to reprogram the mice’s own glia cells to become nerve cells. “The research findings have the potential to open the way for alternatives to cell transplants in the future, which would remove previous obstacles to research, such as the difficulty of getting the brain to accept foreign cells, and the risk of tumor development,” said Dr. Parmar.

The new technique of direct reprogramming in the brain could create new ways to more successfully replace dying brain cells in disorders such as Parkinson’s disease. “We are now developing the technique so that it can be used to create new nerve cells that replace the function of damaged cells. Being able to carry out the reprogramming in vivo makes it possible to imagine a future in which we form new cells directly in the human brain, without taking a detour via cell cultures and transplants,” concluded Dr. Parmar.

The study’s findings were published March 26, 2012, in the journal Proceedings of the National Academy of Science of the United States of America (PNAS).

Related Links:

Lund University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.